GSK-spinoff Haleon forecasts 2023 organic revenue growth at top-end of view

This post was originally published on this site

https://i-invdn-com.investing.com/trkd-images/LYNXMPEJ3J07M_L.jpg

The company, the world’s biggest standalone consumer health business that sells non-prescription drugs, vitamins and oral care products, kept the rest of its full-year 2023 outlook unchanged.

Haleon was carved out of British drugmaker GSK in July last year.